Nkarta receives nkx019 ind clearance from u.s. food and drug administration for treatment of relapsed/refractory b cell malignancies

South san francisco, calif., april 28, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced that the u.s. food & drug administration (fda) has cleared an investigational new drug (ind) application to study nkx019 in patients with relapsed or refractory b cell malignancies.
NKTX Ratings Summary
NKTX Quant Ranking